

Mitja Lainscak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5230342/publications.pdf>

Version: 2024-02-01

242
papers

19,872
citations

25034

57
h-index

13771

129
g-index

245
all docs

245
docs citations

245
times ranked

15982
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
3	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure, 2017, 19, 1574-1585.	7.1	568
4	European Society of Cardiology Heart Failure Long-Term Registry (<scp>ESCâ€HFâ€LT</scp>): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	7.1	538
5	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
6	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	7.1	490
7	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	7.1	446
8	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
9	Sarcopenia: A Time for Action. An SCWD Position Paper. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 956-961.	7.3	410
10	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384
11	Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 115-126.	7.1	318
12	Cardiac cachexia: A systematic overview. , 2009, 121, 227-252.		297
13	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2017, 19, 821-836.	7.1	252
14	Epidemiology, pathophysiology and contemporary management of cardiogenic shockâ€“A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
15	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
16	European Society of Cardiology Heart Failure Association Standards for delivering heart failure care. European Journal of Heart Failure, 2011, 13, 235-241.	7.1	197
17	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	7.1	181
18	Acute heart failure congestion and perfusion statusâ€“Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Long-Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	7.1	170

#	ARTICLE	IF	CITATIONS
19	Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. <i>International Journal of Cardiology</i> , 2016, 222, 41-46.	1.7	166
20	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	7.1	160
21	Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , 2011, 13, 670-680.	7.1	157
22	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	7.1	157
23	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.1	144
24	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. <i>European Heart Journal</i> , 2013, 34, 30-38.	2.2	139
25	Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 1580-1587.	7.1	139
26	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	7.1	138
27	The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2010, 1, 35-42.	7.3	135
28	Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 81-86.	7.3	134
29	The <scp>Heart Failure Association Atlas</scp>: <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	7.1	130
30	The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 399-406.	1.6	125
31	Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. <i>International Journal of Cardiology</i> , 2015, 200, 25-29.	1.7	123
32	Drug-drug interaction software in clinical practice: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 131-142.	1.9	123
33	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	3.0	113
34	Cachexia as a major public health problem: frequent, costly, and deadly. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2013, 4, 173-178.	7.3	111
35	Factors related to self-care behaviours in heart failure: A systematic review of European Heart Failure Self-Care Behaviour Scale studies. <i>European Journal of Cardiovascular Nursing</i> , 2017, 16, 272-282.	0.9	108
36	The obesity paradox in chronic disease: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 1-4.	7.3	106

#	ARTICLE	IF	CITATIONS
37	Under-representation of elderly and women in clinical trials. <i>International Journal of Cardiology</i> , 2017, 232, 216-221.	1.7	105
38	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. <i>International Journal of Cardiology</i> , 2016, 205, 6-12.	1.7	104
39	Cardiac cachexia: hic et nunc. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 246-260.	7.3	103
40	Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
41	Body composition changes in patients with systolic heart failure treated with beta blockers: A pilot study. <i>International Journal of Cardiology</i> , 2006, 106, 319-322.	1.7	88
42	Inflammatory Biomarkers in Heart Failure Revisited: Much More than Innocent Bystanders. <i>Heart Failure Clinics</i> , 2009, 5, 549-560.	2.1	87
43	Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 100-110.	7.1	86
44	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	7.1	83
45	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	7.1	81
46	Pharmacokinetics of Drugs in Cachectic Patients: A Systematic Review. <i>PLoS ONE</i> , 2013, 8, e79603.	2.5	79
47	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	2.2	78
48	Muscle wasting as an independent predictor of survival in patients with chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1242-1249.	7.3	76
49	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2010, 1, 187-194.	7.3	75
50	Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. <i>Respiratory Medicine</i> , 2011, 105, S44-S49.	2.9	74
51	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1615-1633.	7.1	74
52	Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. <i>International Journal of Cardiology</i> , 2009, 132, 303-311.	1.7	67
53	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium-glucose cotransporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
54	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , 2013, 15, 1296-1303.	7.1	63

#	ARTICLE	IF	CITATIONS
55	Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. <i>Clinical Research in Cardiology</i> , 2019, 108, 203-211.	3.3	62
56	International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey. <i>European Journal of Heart Failure</i> , 2007, 9, 292-299.	7.1	61
57	Cancer Cachexia and Related Metabolic Dysfunction. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2321.	4.1	59
58	Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis. <i>European Journal of Heart Failure</i> , 2007, 9, 1095-1103.	7.1	58
59	Atrial fibrillation in chronic non-cardiac disease: Where do we stand?. <i>International Journal of Cardiology</i> , 2008, 128, 311-315.	1.7	58
60	Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. <i>International Journal of Cardiology</i> , 2012, 161, 156-159.	1.7	57
61	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2018, 20, 1081-1099.	7.1	57
62	To eat or not to eat? Indicators for reduced food intake in 91,245 patients hospitalized on nutritionDays 2006-2014 in 56 countries worldwide: a descriptive analysis. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 1393-1402.	4.7	56
63	Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>ESC Heart Failure</i> , 2017, 4, 448-457.	3.1	56
64	Cachexia: Common, Deadly, With an Urgent Need for Precise Definition and New Therapies. <i>American Journal of Cardiology</i> , 2008, 101, S8-S10.	1.6	55
65	Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. <i>JACC: Heart Failure</i> , 2019, 7, 823-833.	4.1	55
66	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1890-1897.	1.6	54
67	Self-rated health and mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 518-524.	7.1	53
68	Discharge Coordinator Intervention Prevents Hospitalizations in Patients With COPD: A Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2013, 14, 450.e1-450.e6.	2.5	53
69	Patient's View of Heart Failure: From the Understanding to the Quality of Life. <i>European Journal of Cardiovascular Nursing</i> , 2003, 2, 275-281.	0.9	52
70	Heart Failure Association of the <sc>European Society of Cardiology</sc> Specialist Heart Failure Curriculum. <i>European Journal of Heart Failure</i> , 2014, 16, 151-162.	7.1	52
71	National trends in heart failure hospitalization rates in Slovenia 2004-2012. <i>European Journal of Heart Failure</i> , 2016, 18, 1321-1328.	7.1	51
72	Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. <i>Clinical Research in Cardiology</i> , 2008, 97, 578-586.	3.3	50

#	ARTICLE	IF	CITATIONS
73	Association of adiponectin with peripheral muscle status in elderly patients with heart failure. <i>European Journal of Internal Medicine</i> , 2013, 24, 818-823.	2.2	50
74	Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	3.1	50
75	Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 191-200.	7.3	49
76	Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF. <i>JACC: Heart Failure</i> , 2016, 4, 140-149.	4.1	49
77	Iron deficiency in heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2368-2379.	3.1	49
78	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the <sc>ESCâ€HFA EORP</sc> Heart Failure Longâ€Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	7.1	49
79	The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 291-296.	1.9	48
80	Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. <i>Clinical Research in Cardiology</i> , 2010, 99, 107-113.	3.3	47
81	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	7.1	47
82	Mechanism and novel therapeutic approaches to wasting in chronic disease. <i>Maturitas</i> , 2013, 75, 199-206.	2.4	46
83	Longâ€term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensinâ€converting enzymes/angiotensin receptor blockers: results from AMETHYSTâ€DN. <i>ESC Heart Failure</i> , 2018, 5, 592-602.	3.1	45
84	The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 309-313.	1.9	44
85	Selfâ€rated health, nutritional intake and mortality in adult hospitalized patients. <i>European Journal of Clinical Investigation</i> , 2014, 44, 813-824.	3.4	44
86	Clinical-pharmacist intervention reduces clinically relevant drugâ€drug interactions in patients with heart failure: A randomized, double-blind, controlled trial. <i>International Journal of Cardiology</i> , 2016, 203, 647-652.	1.7	43
87	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	7.1	41
88	Treatment of chronic heart failure with carvedilol in daily practice: The SATELLITE survey experience. <i>International Journal of Cardiology</i> , 2007, 122, 149-155.	1.7	40
89	GuÃa ESC 2021 sobre el diagnÃstico y tratamiento de la insuficiencia cardiaca aguda y crÃnica. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 523.e1-523.e114.	1.2	40
90	Self-Rated Health Predicts Acute Exacerbations and Hospitalizations in Patients With COPD. <i>Chest</i> , 2010, 138, 323-330.	0.8	37

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 191-198.	1.7	37
92	“Time is prognosis”™ in heart failure: time to treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	3.1	37
93	Emerging Biomarkers in Heart Failure and Cardiac Cachexia. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23878-23896.	4.1	36
94	Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 1015-1021.	7.1	36
95	Fluid Therapy: Double-Edged Sword during Critical Care?. <i>BioMed Research International</i> , 2015, 2015, 1-14.	1.9	36
96	Increased Myogenic and Protein Turnover Signaling in Skeletal Muscle of Chronic Obstructive Pulmonary Disease Patients With Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 637.e1-637.e11.	2.5	36
97	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	7.1	36
98	How does cachexia influence survival in cancer, heart failure and other chronic diseases?. <i>Current Opinion in Supportive and Palliative Care</i> , 2007, 1, 299-305.	1.3	35
99	The Effects of 8 Weeks of Endurance Running on Hepcidin Concentrations, Inflammatory Parameters, and Iron Status in Female Runners. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2012, 22, 55-63.	2.1	35
100	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
101	Mini nutritional assessment, body composition, and hospitalisations in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2011, 105, S38-S43.	2.9	34
102	Exercise-Induced Changes in Iron Status and Hepcidin Response in Female Runners. <i>PLoS ONE</i> , 2013, 8, e58090.	2.5	34
103	Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 45-52.	7.3	34
104	Effect of selective and non-selective β -blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. <i>Clinical Research in Cardiology</i> , 2008, 97, 24-31.	3.3	33
105	Biomarkers for Chronic Heart Failure. <i>Herz</i> , 2009, 34, 589-593.	1.1	33
106	Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. <i>Archives of Medical Science</i> , 2014, 5, 920-932.	0.9	33
107	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	7.1	33
108	<sc>COVID</sc>-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	7.1	32

#	ARTICLE	IF	CITATIONS
109	Atrial natriuretic peptide and related peptides. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1259-67.	2.3	30
110	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 132-142.	7.1	30
111	ACT ONE ACTION at last on cancer cachexia by adapting a novel action beta blocker. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 400-402.	7.3	29
112	Validation of Self Assessment Patient Knowledge Questionnaire for Heart Failure Patients. <i>European Journal of Cardiovascular Nursing</i> , 2005, 4, 269-272.	0.9	28
113	Nonpharmacologic Measures and Drug Compliance in Patients with Heart Failure: Data from the EuroHeart Failure Survey. <i>American Journal of Cardiology</i> , 2007, 99, S31-S37.	1.6	28
114	Sarcopenia in Advanced COPD Affects Cardiometabolic Risk Reduction by Short-Term High-intensity Pulmonary Rehabilitation. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 814-820.	2.5	28
115	Measuring self-care in patients with heart failure: A review of the psychometric properties of the European Heart Failure Self-Care Behaviour Scale (EHFScBS). <i>Patient Education and Counseling</i> , 2017, 100, 1304-1313.	2.2	28
116	Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges. <i>ESC Heart Failure</i> , 2015, 2, 103-107.	3.1	27
117	Prognostic Factors in Chronic Heart Failure. <i>Herz</i> , 2009, 34, 141-147.	1.1	26
118	Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study. <i>ESC Heart Failure</i> , 2018, 5, 288-296.	3.1	26
119	Bone in heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 381-393.	7.3	25
120	Ghrelin and Neurohumoral Antagonists in the Treatment of Cachexia Associated with Cardiopulmonary Disease. <i>Internal Medicine</i> , 2006, 45, 837-837.	0.7	24
121	Adherence to treatment guidelines and long-term survival in hospitalized patients with chronic obstructive pulmonary disease. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 737-743.	1.8	24
122	What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. <i>European Journal of Heart Failure</i> , 2016, 18, 66-70.	7.1	24
123	Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. <i>European Journal of Heart Failure</i> , 2020, 22, 763-774.	7.1	24
124	Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 293-296.	1.9	23
125	Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2011, 105, S12-S19.	2.9	23
126	Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5627.	4.1	23

#	ARTICLE	IF	CITATIONS
127	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. ESC Heart Failure, 2020, 7, 2098-2112.	3.1	23
128	The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645.	7.1	23
129	Effectiveness of discharge-coordinator intervention in patients with chronic obstructive pulmonary disease: study protocol of a randomized controlled clinical trial. Respiratory Medicine, 2011, 105, S26-S30.	2.9	22
130	Doping awareness, views, and experience: a comparison between general practitioners and pharmacists. Wiener Klinische Wochenschrift, 2012, 124, 32-38.	1.9	22
131	Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. International Journal of Cardiology, 2012, 155, 160-166.	1.7	21
132	Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia. Nutrition, 2014, 30, 1069-1075.	2.4	21
133	Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Internal and Emergency Medicine, 2016, 11, 519-527.	2.0	21
134	heartfailurematters.org™, an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. European Journal of Heart Failure, 2017, 19, 1447-1454.	7.1	21
135	The Effect of 4-week Rehabilitation on Heart Rate Variability and QTc Interval in Patients with Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 659-669.	1.6	20
136	Public health General public awareness of heart failure: results of questionnaire survey during Heart Failure Awareness Day 2011. Archives of Medical Science, 2014, 2, 355-360.	0.9	19
137	Distinct skeletal muscle molecular responses to pulmonary rehabilitation in chronic obstructive pulmonary disease: a cluster analysis. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 311-322.	7.3	19
138	Patients' knowledge and beta blocker treatment improve prognosis of patients from a heart failure clinic. European Journal of Heart Failure, 2006, 8, 187-190.	7.1	18
139	Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. International Journal of Cardiology, 2011, 147, 47-51.	1.7	18
140	Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: Results from the CIBIS-ELD trial. Clinical Biochemistry, 2012, 45, 117-122.	1.9	18
141	Cardiac cachexia: hic et nunc. International Journal of Cardiology, 2015, 201, e1-e12.	1.7	18
142	Timely and individualized heart failure management: need for implementation into the new guidelines. Clinical Research in Cardiology, 2021, 110, 1150-1158.	3.3	18
143	Implementation of guidelines for management of heart failure in heart failure clinic: effects beyond pharmacological treatment. International Journal of Cardiology, 2004, 97, 411-416.	1.7	17
144	Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. European Journal of Clinical Pharmacology, 2016, 72, 813-822.	1.9	17

#	ARTICLE	IF	CITATIONS
145	Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of bisoprolol, ramiprilat, propranolol and midazolam in rat dried blood spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 958, 29-35.	2.3	16
146	Poor self-rated health predicts mortality in patients with stable chronic heart failure. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, 504-512.	0.9	16
147	Metabolic disturbances in chronic heart failure: A case for the "omach" approach with testosterone?. <i>European Journal of Heart Failure</i> , 2007, 9, 2-3.	7.1	15
148	Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?. <i>European Heart Journal</i> , 2007, 28, 2830-2831.	2.2	15
149	Chronic obstructive pulmonary disease patient journey. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 16, 278-283.	2.5	15
150	Reproducibility of isokinetic knee testing using the novel isokinetic SMM iMoment dynamometer. <i>PLoS ONE</i> , 2020, 15, e0237842.	2.5	15
151	Distribution of self-rated health and association with clinical parameters in patients with chronic obstructive pulmonary disease. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 297-302.	1.9	14
152	Self-care perception and behaviour in patients with heart failure: A qualitative and quantitative study. <i>ESC Heart Failure</i> , 2021, 8, 2079-2088.	3.1	14
153	Infective endocarditis due to <i>Abiotrophia defectiva</i> : a report of two cases. <i>Journal of Heart Valve Disease</i> , 2005, 14, 33-6.	0.5	14
154	Biomarkers for chronic heart failure. <i>Heart Failure Monitor</i> , 2007, 5, 77-82.	0.7	14
155	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.2	14
156	Should procalcitonin be measured routinely in acute decompensated heart failure?. <i>Biomarkers in Medicine</i> , 2015, 9, 651-659.	1.4	13
157	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 1162-1170.	7.1	13
158	Anticoagulants, Antiplatelets, and Statins in Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 49-58.	2.2	12
159	Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2015, 2, 122-128.	3.1	12
160	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	1.6	12
161	Mortality and readmissions in heart failure: an analysis of 36,824 elderly patients from the Slovenian national hospitalization database. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 512-518.	1.9	12
162	Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients. <i>Clinica Chimica Acta</i> , 2017, 473, 127-132.	1.1	12

#	ARTICLE	IF	CITATIONS
163	Living with Chronic Heart Failure: Exploring Patient, Informal Caregiver, and Healthcare Professional Perceptions. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2666.	2.6	12
164	Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study. <i>International Journal of Cardiology</i> , 2012, 161, 137-142.	1.7	11
165	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. <i>Frontiers in Physiology</i> , 2018, 9, 1000.	2.8	11
166	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	1.8	11
167	Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1570-1578.	2.9	11
168	Feasibility of transcutaneous electrical muscle stimulation in acute exacerbation of COPD. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 384-387.	1.9	10
169	Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. <i>Archives of Medical Science</i> , 2013, 2, 261-267.	0.9	10
170	Impact of chronic inflammatory airway disease on stroke severity and long-term survival after ischemic stroke - a retrospective analysis. <i>BMC Neurology</i> , 2015, 15, 164.	1.8	10
171	Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial. <i>International Journal of Cardiology</i> , 2016, 222, 885-887.	1.7	10
172	Androgen status in non-diabetic elderly men with heart failure. <i>Aging Male</i> , 2017, 20, 215-224.	1.9	10
173	The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. <i>Clinica Chimica Acta</i> , 2020, 510, 507-514.	1.1	10
174	Effects of high-load and low-load resistance training in patients with coronary artery disease: rationale and design of a randomised controlled clinical trial. <i>BMJ Open</i> , 2021, 11, e051325.	1.9	10
175	Effects of high- and low-load resistance training in patients with coronary artery disease: a randomized controlled clinical trial. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e338-e342.	1.8	10
176	Self-rated health predicts adverse events during beta-blocker treatment: The CIBIS-ELD randomised trial analysis. <i>International Journal of Cardiology</i> , 2013, 163, 87-92.	1.7	9
177	The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure. <i>International Journal of Cardiology</i> , 2016, 212, 187-189.	1.7	9
178	The management of patients with heart failure in a Slovenian community hospital: What has changed between 1997 and 2000?. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 334-339.	1.9	8
179	Comorbidities in Chronic Obstructive Pulmonary Disease from Assessment to Treatment. <i>BioMed Research International</i> , 2014, 2014, 1-2.	1.9	8
180	Cancer cachexia: an orphan with a future. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 3-5.	7.3	8

#	ARTICLE	IF	CITATIONS
181	Hemodynamic Response to High- and Low-Load Resistance Exercise in Patients with Coronary Artery Disease: A Randomized, Crossover Clinical Trial. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3905.	2.6	8
182	Heart failure and chronic obstructive pulmonary disease: Two for tea or tea for two?. <i>World Journal of Cardiology</i> , 2010, 2, 305.	1.5	8
183	<i>In vitro</i> Stability of Heat Shock Protein 27 in Serum and Plasma Under Different Pre-analytical Conditions: Implications for Large-Scale Clinical Studies. <i>Annals of Laboratory Medicine</i> , 2016, 36, 353-357.	2.5	7
184	Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy. <i>Radiology and Oncology</i> , 2016, 51, 15-22.	1.7	7
185	Heart failure prevalence in the general population: SOBOTAâ€”HF study rationale and design. <i>ESC Heart Failure</i> , 2019, 6, 1077-1084.	3.1	7
186	Heart failure clinic in a community hospital improves outcome in heart failure patients. <i>Swiss Medical Weekly</i> , 2006, 136, 274-80.	1.6	7
187	Subcutaneous infection with <i>Pseudallescheria boydii</i> in an immunocompromised patient. <i>Clinical Rheumatology</i> , 2007, 26, 1023-1024.	2.2	6
188	Doping and the Olympic games: the good, the bad, and the ugly. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 13-14.	1.9	6
189	Psychocardiology in the elderly. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 474-479.	1.9	6
190	Heat shock protein 27 as a predictor of prognosis in patients admitted to hospital with acute COPD exacerbation. <i>Cell Stress and Chaperones</i> , 2020, 25, 141-149.	2.9	6
191	Knowledge and skills required to perform point-of-care ultrasonography in family practice â€” a modified Delphi study among family physicians in Slovenia. <i>BMC Family Practice</i> , 2020, 21, 56.	2.9	6
192	Sodiumâ€”glucose cotransporter 2 inhibitorâ€”induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2631-2636.	3.1	6
193	Objectively Measured Physical Activity in Patients with Coronary Artery Disease: A Cross-Validation Study. <i>Biosensors</i> , 2021, 11, 318.	4.7	6
194	Education and certification on heart failure of the <i>Heart Failure Association of the European Society of Cardiology</i> . <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	7.1	6
195	High-Load and Low-Load Resistance Exercise in Patients with Coronary Artery Disease: Feasibility and Safety of a Randomized Controlled Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3567.	2.4	6
196	Overview of emerging pharmacotherapy in chronic heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2055-2074.	1.8	5
197	Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. <i>Croatian Medical Journal</i> , 2015, 56, 531-541.	0.7	5
198	Therapy modifications during hospitalization in patients with chronic heart failure. <i>European Journal of Internal Medicine</i> , 2016, 29, 52-58.	2.2	5

#	ARTICLE	IF	CITATIONS
199	Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 645-655.	3.3	5
200	How to Improve Adherence to Life-saving Heart Failure Treatments with Potassium Binders. <i>Cardiac Failure Review</i> , 2017, 03, 33.	3.0	5
201	Regional differences in heart failure hospitalizations, mortality, and readmissions in Slovenia 2004–2012. <i>ESC Heart Failure</i> , 2019, 6, 965-974.	3.1	4
202	Challenges of Beta Blocker Therapy in Chronic Heart Failure: The Story Continues. <i>European Journal of Cardiovascular Nursing</i> , 2008, 7, 159-160.	0.9	3
203	Venous thromboembolism prophylaxis in hospitalized patients with pneumonia: a prospective survey. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 318-323.	1.9	3
204	Education, knowledge, and self-management strategies in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2010, 144, 92-93.	1.7	3
205	No train, no gain: Does this apply to heart failure with preserved ejection fraction?. <i>International Journal of Cardiology</i> , 2013, 162, 69-70.	1.7	3
206	Biological and chronological age in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 857-859.	1.5	3
207	PURE muscle and more. <i>International Journal of Cardiology</i> , 2016, 202, 446-447.	1.7	3
208	Echocardiographic predictors of outcome in patients with chronic obstructive pulmonary disease. <i>Journal of Clinical Ultrasound</i> , 2017, 45, 211-221.	0.8	3
209	Procalcitonin in heart failure: <i>hic et nunc</i> . <i>Biomarkers in Medicine</i> , 2017, 11, 893-903.	1.4	3
210	Acute effects of oral triglyceride load on dynamic changes in peripheral endothelial function in heart failure patients with reduced ejection fraction and healthy controls. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1961-1966.	2.6	3
211	Natriuretic peptides for heart failure screening in nursing homes: a systematic review. <i>Heart Failure Reviews</i> , 2020, 26, 1131-1140.	3.9	3
212	Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium–glucose co–transporter 2 inhibitors?. <i>European Journal of Heart Failure</i> , 2021, 23, 644-647.	7.1	3
213	Is blood flow restriction resistance training the missing piece in cardiac rehabilitation of frail patients?. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 117-122.	1.8	3
214	Importance of bedside echocardiography for detection of unsuspected isolated right ventricular infarction as a cause of cardiovascular collapse. <i>American Journal of Emergency Medicine</i> , 2007, 25, 110-114.	1.6	2
215	Beta-Blockers in Elderly Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2202.	2.8	2
216	Electrocardiogram Analysis and Survival of Patients With Chronic Obstructive Pulmonary Disease. <i>Chest</i> , 2011, 140, 575A.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Left ventricular metastasis of soft tissue sarcoma causing heart failure: Presentation of two cases. <i>International Journal of Cardiology</i> , 2016, 219, 119-120.	1.7	2
218	The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians. <i>ESC Heart Failure</i> , 2020, 7, 873-877.	3.1	2
219	Pharmacotherapy adherence in patients with heart failure: Easier said than done. <i>International Journal of Cardiology</i> , 2021, 332, 135-137.	1.7	2
220	Optimizing cardiopulmonary rehabilitation of long COVID-19 syndrome: are we there yet?. <i>European Journal of Preventive Cardiology</i> , 2022, , .	1.8	2
221	Assessment of physical fitness in adults by field testing supported by the specific software for personal computer based use. <i>Computers in Biology and Medicine</i> , 2007, 37, 1377-1383.	7.0	1
222	Smoking cessation in heart failure: easier said than done. <i>European Heart Journal</i> , 2009, 30, 624-625.	2.2	1
223	Functional capacity in heart failure with preserved ejection fraction: Looking for interactions and explanations. <i>International Journal of Cardiology</i> , 2014, 172, 295-296.	1.7	1
224	The β -blocker uptitration in elderly with heart failure regarding biomarker levels: CIBIS-ELD substudy. <i>Biomarkers in Medicine</i> , 2018, 12, 1261-1270.	1.4	1
225	Exercise training in cardiovascular disease: are we closing the gender gap?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2057-2058.	1.8	1
226	Fractional heat shock protein 27 urine excretion as a short-term predictor in acute exacerbation of chronic obstructive pulmonary disease. <i>Annals of Translational Medicine</i> , 2021, 9, 117-117.	1.7	1
227	Optimisation of Heart Failure Management in Nursing Homes Using Point-of-Care Ultrasonography: Harmonious Trial Rationale and Design. <i>Zdravstveno Varstvo</i> , 2020, 59, 128-136.	0.9	1
228	Exercise intolerance in heart failure: beyond mitochondrial dysfunction. Letter regarding the article "Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?" TM . <i>European Journal of Heart Failure</i> , 2022, 24, 910-910.	7.1	1
229	Survival and body fat in hemodialysis patients: true association or effects of concomitant therapy?. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 663-664.	4.7	0
230	From surveys to trials in the beta blocker world. <i>International Journal of Cardiology</i> , 2009, 136, 94-95.	1.7	0
231	Battlescarred. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1514.	2.8	0
232	Self-rated health, beta-blockers and adverse events. <i>International Journal of Cardiology</i> , 2014, 171, 466-467.	1.7	0
233	Cardiovascular Function in Intensive Care Medicine or Homo Mensura Est. <i>BioMed Research International</i> , 2016, 2016, 1-3.	1.9	0
234	Nutritional status in the elderly: misbeliefs, misconceptions and the real world. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 427-429.	1.9	0

#	ARTICLE	IF	CITATIONS
235	Physical and psychological status of patients with COPD and impaired LVEF: Two bads don't make a good. <i>International Journal of Cardiology</i> , 2017, 227, 249-250.	1.7	0
236	Balancing cardiac rehabilitation for elderly. <i>European Journal of Preventive Cardiology</i> , 2020, 28, e37-e38.	1.8	0
237	P0816CLINICAL CHARACTERISTICS AND EGFR AND UACR DISTRIBUTION ACCORDING TO THE 2012 KDIGO CKD CLASSIFICATION: A REPORT FROM THE US DISCOVER CKD COHORT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
238	Response: Commentary: Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. <i>Frontiers in Physiology</i> , 2021, 12, 665568.	2.8	0
239	Beware of TOSCA's kiss or metabolic and hormonal aspects of heart failure. <i>European Journal of Preventive Cardiology</i> , 2021, , .	1.8	0
240	Zadovoljstvo bolnikov s kronično obstruktivno pljučno boleznijo z obravnavo koordinatorja odpusta. <i>Obzornik Zdravstvene Nege</i> , 2015, 49, .	0.1	0
241	Embracing secondary mitral regurgitation with Carillon: past, present, and future. <i>ESC Heart Failure</i> , 2020, 7, 3268-3270.	3.1	0
242	Nonlinear Heart Rate Variability in Patients with Chronic Obstructive Pulmonary Disease and Changes after 4-week Comprehensive Inpatient Pulmonary Rehabilitation.. <i>Nonlinear Dynamics, Psychology, and Life Sciences</i> , 2022, 26, 149-162.	0.2	0